CXCR4 and leukemia: Plerixafor, as a targeted CXCR4 inhibitor (FDA-approved), mobilizes leukemia cells post-hematopoietic cell transplantation, sensitizing them to cytotoxic therapy and enhancing healthy donor stem cell engraftment [102].